Overview

Single Dose Two-Way Crossover Fed Bioequivalence Study of Nabumetone 750 mg Tablets in Healthy Volunteers

Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the relative bioavailability of two formulations of nabumetone tablets to establish their average bioequivalence
Phase:
Phase 1
Details
Lead Sponsor:
Actavis Inc.
Treatments:
Nabumetone